Intravitreal Bevacizumab Avastin, Roche, United Kingdom for exudative maculopathies - Intravitreal bevacizumab

• Conditions: Exudative maculopathy associated with retinovascular disease; MedDRA version: 6.1Level: PTClassification code 10012689

• Registration Number: EUCTR2005-006182-14-IT
• Lead Sponsor: IVERSITA DEGLI STUDI DI UDINE

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-02-17
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

- Patients with diffuse clinically significant diabetic macular edema CSDME ETDRS criteria either unresponsive to prior treatments laser or intravitreal triamcinolone or combined or very severe at initial presentation - Patients with nonischemic branch retinal vein occlusion BRVO or central retinal vein occlusion CRVO and severe cystoid macular edema either unresponsive to prior treatments or persisting after 6 months since initial presentation - Patients with age-related macular degeneration AMD and subfoveal choroidal neovascularization CNV either unresponsive to prior PDT or unlikely to respond to PDT large subretinal hemorrhage, large PED, large minimally classic lesion, chorioretinal anastomosis - Patients with age-related macular degeneration AMD and stage II-III retinal angiomatous proliferation RAP
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

EYE - History of any ocular surgery within the previous 6 months - Significant media opacities - Macular ischemia at fluorescein angiography MEDICAL - Chronic liver disease, clinical jaundice, and/or elevation of liver-related laboratory results 2 times the upper limit of normal - Chronic renal failure on dialysis - Stroke - Congestive heart failure or myocardial infarction - Cancer

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified